NFATC2 and gastric cancer: In gastric cancer (GC), the transient receptor potential canonical 3 (TRPC3) promotes tumorigenesis via the CNB2/GSK3β/NFATc2 signaling pathway; thus, TRPC3 could be a possible target for therapeutic intervention [27].